Recent Posts
- Eyenovia Reveals Positive Evidence that Optejet® Delivery Technology Decreased Inflammation from Preserved Glaucoma Solutions Compared to Drops January 13, 2023
- Eyenovia Announces FDA Acceptance of New Drug Application for MydCombiâ„¢ for In-Office Pupil Dilation December 13, 2022
- Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund November 29, 2022
Pipeline and Technology
Corporate Address
Eyenovia, Inc.
295 Madison Avenue
Suite 2400
New York, NY 10017
admin@eyenoviabio.com
